Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FOXO1-IN-3 is a highly-selective, orally active inhibitor of FOXO1 that diminishes hepatic glucose production and enhances insulin sensitivity and glucose regulation in db/db mice, all without inducing weight gain [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | FOXO1-IN-3 is a highly-selective, orally active inhibitor of FOXO1 that diminishes hepatic glucose production and enhances insulin sensitivity and glucose regulation in db/db mice, all without inducing weight gain [1]. |
In vitro | FOXO1-IN-3 (Compound 10) at a concentration of 10 μM after 6 hours of treatment inhibits the expression of G6pc and Pck1 mRNA induced by cAMP/Dexamethasone in primary hepatocytes from normal mice [1]. |
In vivo | FOXO1-IN-3 (Compound 10) (16 mg/kg, oral administration, twice daily for 10 days) effectively reduced blood glucose levels in db/db mice [1]. Furthermore, synergistic glucose-lowering effects were observed in Streptozotocin -induced diabetic mice with depleted β-cells when FOXO1-IN-3 (16 mg/kg, orally, twice daily for 7 days) was combined with FGF21 (0.45 mg/kg) [1]. FOXO1-IN-3 demonstrated significant plasma exposure and oral bioavailability in mice when administered intravenously at 1 mg/kg and orally at 10 mg/kg, despite a relatively short half-life [1]. |
Molecular Weight | 401.46 |
Formula | C22H23N7O |
CAS No. | 2451093-95-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FOXO1-IN-3 2451093-95-9 Others inhibitor inhibit